Those determined to outshine the market strategically focus on the selection of individual stocks. Well-chosen stocks have the potential to substantially boost your wealth.
After finishing at $81.66 in the prior trading day, Ionis Pharmaceuticals Inc (NASDAQ: IONS) closed at $79.48, down -2.67%. In other words, the price has decreased by -$2.67 from its previous closing price. On the day, 1.89 million shares were traded. IONS stock price reached its highest trading level at $82.57 during the session, while it also had its lowest trading level at $78.61.
Ratios:
Our goal is to gain a better understanding of IONS by taking a closer look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 2.78 and its Current Ratio is at 2.79. In the meantime, Its Debt-to-Equity ratio is 3.32 whereas as Long-Term Debt/Eq ratio is at 2.27.
On September 26, 2025, Goldman Upgraded its rating to Neutral which previously was Sell but kept the price unchanged to $65.
BMO Capital Markets Upgraded its Market Perform to Outperform on September 03, 2025, while the target price for the stock was maintained at $70.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Jan 07 ’26 when Devers Shannon L. sold 44,199 shares for $85.08 per share. The transaction valued at 3,760,577 led to the insider holds 17,494 shares of the business.
Devers Shannon L. bought 9,390 shares of IONS for $795,117 on Jan 07 ’26. On Jan 02 ’26, another insider, Swayze Eric, who serves as the EVP Research of the company, sold 23,463 shares for $79.12 each. As a result, the insider received 1,856,325 and left with 30,453 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, IONS now has a Market Capitalization of 12873725952 and an Enterprise Value of 12689773568. For the stock, the TTM Price-to-Sale (P/S) ratio is 13.31 while its Price-to-Book (P/B) ratio in mrq is 20.72. Its current Enterprise Value per Revenue stands at 13.123 whereas that against EBITDA is -47.563.
Stock Price History:
The Beta on a monthly basis for IONS is 0.29, which has changed by 1.4588978 over the last 52 weeks, in comparison to a change of 0.1726681 over the same period for the S&P500. Over the past 52 weeks, IONS has reached a high of $86.15, while it has fallen to a 52-week low of $23.95. The 50-Day Moving Average of the stock is 1.87%, while the 200-Day Moving Average is calculated to be 48.84%.
Shares Statistics:
The stock has traded on average 2.35M shares per day over the past 3-months and 1900170 shares per day over the last 10 days, according to various share statistics. A total of 161.14M shares are outstanding, with a floating share count of 158.81M. Insiders hold about 1.95% of the company’s shares, while institutions hold 106.74% stake in the company. Shares short for IONS as of 1767139200 were 14885370 with a Short Ratio of 6.34, compared to 1764288000 on 15626208. Therefore, it implies a Short% of Shares Outstanding of 14885370 and a Short% of Float of 12.1300004.
Earnings Estimates
. The current market rating for Ionis Pharmaceuticals Inc (IONS) reflects the collective analysis of 6.0 analysts closely monitoring its performance.The consensus estimate for the next quarter is -$0.47, with high estimates of -$0.34 and low estimates of -$0.6.
Analysts are recommending an EPS of between -$1.43 and -$1.87 for the fiscal current year, implying an average EPS of -$1.69. EPS for the following year is -$2.32, with 9.0 analysts recommending between -$1.08 and -$3.39.
Revenue Estimates
14 analysts predict $152.84M in revenue. The current quarter. It ranges from a high estimate of $176.1M to a low estimate of $124.5M. As of. The current estimate, Ionis Pharmaceuticals Inc’s year-ago sales were $227MFor the next quarter, 14 analysts are estimating revenue of $196.97M. There is a high estimate of $241.6M for the next quarter, whereas the lowest estimate is $145.53M.
A total of 20 analysts have provided revenue estimates for IONS’s current fiscal year. The highest revenue estimate was $922.7M, while the lowest revenue estimate was $865.1M, resulting in an average revenue estimate of $896.41M. In the same quarter a year ago, actual revenue was $705MBased on 20 analysts’ estimates, the company’s revenue will be $912.38M in the next fiscal year. The high estimate is $1.15B and the low estimate is $686.83M.
